Please login to the form below

Not currently logged in


This page shows the latest Tesaro news and features for those working in and with pharma, biotech and healthcare.

AZ and MSD surpass rivals with updated Lynparza data

AZ and MSD surpass rivals with updated Lynparza data

Rival Tesaro is also expecting phase III results in the same setting for its PARP inhibitor Zejula (niraparib), but much like Lynparza, that data won’t be available until next year.

Latest news

More from news
Approximately 8 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Licence. 339. TeneoBio/TESARO. Multi-specific antibodies for up to six undisclosed oncology targets using UniRat® platform and discovery engine TeneoSeek.

  • Deal Watch February 2017 Deal Watch February 2017

    There has been speculation for several months that oncology company Tesaro may be the target for a large pharma bid and as a result its share price has increased by 570%

  • Deal Watch April 2016 Deal Watch April 2016

    Apart from the 3 deals by Abbvie, there were deals by GSK and Janssen with Zymeworks and Tesaro respectively. ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP inhibitor in clinical phase for treatment of prostate cancer.

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    350.5. AnaptysBio/ Tesaro. Collaboration, licence. mAbs to activate immune system response "checkpoints" - 3 targets: TIM-3, LAG-3 and PD-1 (preclinical).

  • Pharma deals during March 2014 Pharma deals during March 2014

    The second deal, the $341m discovery transaction between AnaptysBio and Tesaro, is focused on the development of antibodies that activate immune checkpoints disabled by various cancers.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....